Next Article in Journal
Modulation of the Apurinic/Apyrimidinic Endonuclease Activity of Human APE1 and of Its Natural Polymorphic Variants by Base Excision Repair Proteins
Next Article in Special Issue
PIMT Binding to C-Terminal Ala459 of CAIX Is Involved in Inside-Out Signaling Necessary for Its Catalytic Activity
Previous Article in Journal
Advantages in Wound Healing Process in Female Mice Require Upregulation A2A-Mediated Angiogenesis under the Stimulation of 17β-Estradiol
Previous Article in Special Issue
Interplay between Carbonic Anhydrases and Metallothioneins: Structural Control of Metalation
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 21
Issue 19
10.3390/ijms21197146
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Carbonic Anhydrase IX in Renal Cell Carcinoma, Implications for Disease Management

by
Jean Courcier
1,2,
Alexandre de la Taille
2,
Maya Nourieh
3,
Ingrid Leguerney
1,
Nathalie Lassau
1,4 and
Alexandre Ingels
1,2,*
1
Biomaps, UMR1281, INSERM, Centre National de la Recherche Scientifique (CNRS), Commissariat à l’Energie Atomique (CEA), Université Paris Saclay, 94800 Villejuif, France
2
Department of Urology, Henri Mondor Hospital, Université Paris Est Créteil (UPEC), 94000 Créteil, France
3
Department of Pathology, Henri Mondor Hospital, UPEC, 94000 Créteil, France
4
Department of Imaging, Institute Gustave Roussy, 94800 Villejuif, France
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(19), 7146; https://doi.org/10.3390/ijms21197146
Submission received: 28 August 2020 / Revised: 17 September 2020 / Accepted: 22 September 2020 / Published: 28 September 2020
(This article belongs to the Special Issue Carbonic Anhydrase and Biomarker Research 2020)
Browse Figures
Versions Notes

Abstract

:
Carbonic Anhydrase IX (CAIX) is a well-described enzyme in renal cell carcinoma, with its expression being regulated by the hypoxia-inducible factor 1 alpha, it is known for interfering with hypoxia processes. Renal carcinoma encompasses a broad spectrum of histological entities and is also described as a heterogeneous malignant tumor. Recently, various combinations of checkpoint inhibitors and targeted therapies have been validated to manage this disease. Reliable markers to confirm the diagnosis, estimate the prognosis, predict or monitor the treatment response are required. Molecular imaging developments allow a comprehensive analysis of the tumor, overcoming the spatial heterogeneity issue. CAIX, being highly expressed at the tumor cell surfaces of clear cell renal carcinoma, also represents a potential treatment target. In this manuscript we reviewed the current knowledge from the literature on the pathophysiological interactions between renal cell carcinoma and CAIX, the role of CAIX as a marker for diagnosis, prognosis, treatment monitoring and molecular imaging, and the potential target for therapeutic strategies.

1. Introduction

Carbonic anhydrase IX (CAIX) is a member of the 14 carbonic anhydrase enzymes isoforms found in humans. It is over-expressed in many types of cancer. Renal cell carcinoma (RCC) represents around 3% of all cancers [1]. Its incidence has increased at a pace of around 2%/year for the last two decades, mostly due to the use of abdominal imaging in routine clinical practices leading to incidental diagnosis of renal tumors. There were some 99,200 new RCC cases and 39,100 kidney cancer-related deaths in 2018 within the European Union [2]. RCC encompasses many different forms of histopathological entities described in the 2016 World Health Organization classification [3]. However, there are three main RCC types: clear cell (ccRCC), papillary (Prcc-type 1 and 2) and chromophobe (chRCC).
CAIX expression was first reported in RCC in 1986, it was then named G250. Since then, many explorations have been performed to define the role of CAIX in RCC and its potential as a diagnostic, prognostic and therapeutic target to manage this disease. The aim of this review was to collect and synthetize the current knowledge on this marker in RCC pathophysiology, diagnostic and treatment.

2. Evidence Acquisition

We performed a literature search using the PubMed database. The search keywords were CAIX, G250 and/or renal carcinoma. We restricted our research to English language publications. We completed our investigations with specific additional keywords such as CAIX and pembrozilumab, ipilimumab, nivolumab, avelumab.

3. Evidence Synthesis

3.1. Role of CAIX in RCC Pathophysiology

CAIX is a trans-membranous protein that is expressed under physiological conditions in certain tissues, essentially the digestive track. Its presence in epithelial cells of the small bowel, duodenum, gastric mucosa and biliary tree has been reported. Conversely, it is widely expressed in several tumors by the action of hypoxia, described in many different types of cancers, such as lung, colorectal, gastric, pancreatic, breast, cervix, bladder, ovaries, brain, head and neck, astrocytomas, and oral cavity cancers [4,5].
Like other trans-membranous proteins, it is made up of three parts: an extracellular proteoglycan-like domain with the carbonate anhydrase (CA), a transmembrane segment and an intracytoplasmic part [6]. CAIX is involved in pH regulation of the cell environment [7].
The external side is responsible for the extracellular reversible catalyzation of the CO2 into bicarbonate by hydration. Transmembrane reabsorption of HCO3– leading to an accumulation of protons in extracellular sector. The acidic cell microenvironment would favorize neo-angiogenesis by stimulating the vascular endothelial growth factor (VEGF) pathway. The internal side contains potential phosphorylation sites, permitting intracellular transduction signals. CAIX has a role on glucose metabolism through its cytoplasmic tail when phosphorylated.
The CAIX expression is regulated by a hypoxia-inducible factor 1 alpha (HIF1-α) [8]: under physiological normoxic conditions, HIF1-α is bound by the Von Hippel Lindau protein (pVHL) leading to its destruction via the ubiquitination and proteasome pathway) [9].
Under hypoxic stress, the affinity between HIF1-α and pVHL is decreased leading to an accumulation of cytoplasmic HIF1-α. This latter will be able to bind HIF1-β to form the HIF1 complex. HIF1 activates the transcription of several hypoxia-inducible genes that contain hypoxia responsive elements (HRE), like those involved in iron metabolism, glucose metabolism, angiogenesis (VEGF) and pH regulation (among which CAIX gene).
In the precise case of ccRCC (clear cell renal cell carcinoma), up to 95% of the tumor genomes are constitutionally VHL gene muted or deleted, thus leading to constitutive activation of HIF1 and CAIX upregulation, even in normoxic conditions.
The comparison of cDNA sequences between cancer and normal cells does not reveal any mutations or alternative splicing [10], and therefore the pathological mutations appear upstream in the signaling pathway. CAIX is also involved in cell adhesion thanks to its capacity to bind β-cathenin leading to a diminishing aptitude to capture E-cadherin which could eventually facilitate the cell migration and spreading [11].

3.2. CAIX as a Diagnostic Marker

3.2.1. In Immunohistochemistry (IHC)

CAIX IHC Detection Permits Diagnosis of Histological Subtype

Renal cell carcinoma (RCC) covers many different subtypes, following the example of the recent new classification (2016 World Health Organization classification) [3]. Also, the pathological diagnosis of RCC subtype relies on the utilization of several tools, among which immunohistochemistry appears nowadays to be essential.
Making a precise diagnosis of the subtype is crucial given the wide alterity of related prognosis. After gross description, diagnosis of RCC, with histological features of the tissue sample, is always the first step before subtype identifying [12]: RCC tumor cells have abundant cytoplasm that is vacuolated, fluffy or granular, usually with indistinct cell borders (chromophobe renal cell carcinoma has distinct borders). Tumor nuclei have variable atypia, irregular contours, haphazard orientation with abnormal chromatin and variably prominent nucleoli (Figure 1).
The second step lies in immunohistochemistry analyses, principally based on three immunomarkers: cytokeratin 7 (CK7), α-methylacyl-CoA racemase (AMACR) and CAIX. These three markers could constitute an initial panel for diagnosis. Kim et al. [13] proposed a two-step strategy for the use of immunostaining in renal cell carcinoma subtype diagnosis: first with the triple panel described above (CK7, AMACR and CAIX) and then, if necessary, with others markers like c-kit, CD10 or cathepsin-K. Another team proposed to enlarge the panel adding the detection of TFE3 (transcription factor binding to IGHM enhancer 3) in IHC, permitting to detect the Xp11 translocation associated RCC [14,15].
The subtypes that stain with CAIX are mainly the clear cell renal cell carcinoma (ccRCC), which is the most common subtype, about 70% of RCC [16], the clear-cell papillary renal cell carcinoma (ccpRCC), and sometimes, with often moderate intensity, the non-type 1 papillary renal cell carcinoma (pRCCII).
It is described that in almost all RCC subtypes, CAIX staining inversely correlates with CK7: the type 1 papillary renal cell carcinoma (pRCCI) is always CK7 positive and CAIX negative. Except for the renal neoplasm of the low-malignant-potential group (ccpRCC and multilocular cystic renal neoplasm of low malignant potential), where both may be positive. ccRCC is considered CAIX positive in IHC. It has also been observed that CAIX is diffusely and intensively staining with a box pattern in ccRCC in 75 to 100% of cases (described as “surrounding each quadrangle border”) when the CAIX may be focally stained in 25% of cases (Figure 2).
Conversely, ccpRCC, where CAIX is often positive, manifests a specific cup-shaped staining of CAIX, with open lumen (Figure 3). ccRCC seems to have the highest expression of CAIX, probably due to the constitutional loss of VHL. As described above, ccRCC could be considered as always CAIX positive [17], while chRCC and pRCC1 are typically CAIX negative [18].

Prognostic Implication of CAIX Detection in IHC

As seen above, CAIX detection plays a major role in histological subtype detection. As the prognostic and evolution of the disease is narrowly correlated with RCC subtype and histological features, CAIX detection in IHC could give crucial prognostic information. Moreover, the principal rational is that High CAIX expression could witness the VHL-associated tumorigenesis, and ccRCC presenting an abnormally low CAIX rate could reflect the tumor de-differentiation and aggressiveness.
Ingels et al. realized a retrospective study on 143 extirpated local ccRCC, and tested 6 markers in IHC on the tumor’s samples: CAIX, c-MYC, Ki67, p53, vimentin and PTEN. The results showed that low CAIX expression (under 30%) and vimentin over-expression (over 50%) were associated with the worst outcomes (overall survival, progression-free survival and disease-free survival). The association of the two biomarkers in IHC (CAIX-/vimentin+) showed a good concordance [19].
Bui et al. [20] described unfavorable disease course in ccRCC with low CAIX expression levels in a study with 321 patients. Zhang et al. [21] and Zerati et al. [22] could not confirm this observation in 730 patients with ccRCC. They suggested that CAIX was not an independent prognostic marker for ccRCC after adjusting for nuclear grade or coagulative tumor necrosis.
Buschek et al. [23] retrospectively analyzed 1809 RCC according to the 2016 WHO classification criteria. CAIX Immunostaining were used in tissue microarray format. Four spots were analyzed for each tumor, so it could not perfectly represent the heterogeneity of the tumors. The staining signal was considered either negative, weak, moderate or strong. For the cohort of ccRCC (1101 tumors), only the ones with strong staining were considered positive. Any pRCC tumor with weak, moderate or strong staining was considered positive (any kind of positive staining). High CAIX expression in the ccRCC group was associated with low ISUP and Furhman grade, low tumor stage and absence of distant metastases. It was also associated with better recurrence-free survival and overall survival. In the pRCC group (252 tumors), only trends were observed between CAIX expression and the clinical-pathological tumor parameters. High expression of CAIX was associated with diminished recurrence-free survival. In other terms, high CAIX expression in ccRCC seemed to be associated with better prognosis, while high CAIX expression in pRCC seemed to be unfavorable.
One meta-analysis [24] treated CAIX expression and clinico-pathological issues. Four studies were mainly retained, namely the articles from Bui et al., Zhang et al. (mentioned above), Patard et al. [25] and Chamie et al. [26] High CAIX expression seemed to be associated with lower tumor stage (pT1T2 vs. pT3T4), lower tumor grade (G1G2 vs. G3G4), absence of nodal involvement (N0 vs. N+) and favorable ECOG score (0 vs. ≥1).
In 2003, Bui et al. demonstrated that 85% of tumor surface staining represents a good cut-off threshold to discriminate high vs. weak immunohistochemistry CAIX staining and to predict survival [20]. In 2014, Ingels et al. found 30% was the best threshold [19].
Chamie et al. proposed another score to measure the CAIX expression: it associates the percentage of stained surface with the staining intensity. This scores range from 0 to 300 (intensity 0 to 3, semiquantitative assessment). A high CAIX score (>200) was associated with prolonged DFS and OS [26]. Evidence on CAIX expression measured by immunohistochemistry and clinical outcomes is summarized in Table 1.
We could hypothesize that an “aberrant” expression of CAIX in RCC tumors exists, which seems to be associated with poor prognosis, may reflect cancer dedifferentiation.

CAIX Measured by Immunohistochemistry and Systemic Treatment Response Prediction

Tostain et al. [27] and Atkins et al. [28] analyzed the correlation between CAIX high expression in RCC metastatic patients and increased tumor sensitivity to interleukin-2 (IL-2). This treatment is no longer recommended in metastatic RCC management [29].
Choueiri et al. [30] assessed the utility of CAIX expression to predict the response in metastatic RCC patients treated with sunitinib or sorafenib, but lacked to enlighten a prognostic value. However, they showed that patients presenting low CAIX expression may benefit less from sorafenib. In another study from the same authors [31], no correlations between CAIX expression and response to sorafenib or IL-2 were observed, leading to the conclusion that CAIX status had no prognostic value. To our knowledge, no studies have been performed so far to assess new immunotherapies treatment such as nivolumab, ipilimumab, pembrozilumab or avelumab through CAIX expression.

3.2.2. Value of Circulating CAIX

Diagnostic Value

Lucarini et al. [32] evaluated the potential of circulating CAIX to diagnose ccRCC. The concentration of circulating CAIX was significantly higher in patients presenting ccRCC in comparison to controls (benign tumors or healthy subjects). The CAIX enzymatic activity showed no differences between the three groups (eight patients each). Pinrinççi et al. [33] also showed significantly increased levels of circulating CAIX in patients afflicted by ccRCC, compared to controls.
Blood sampling of patients with indeterminate tumors on imaging could give an indication of the nature of this tumor.

Prognostic Value

Li et al. measured the plasma levels of CAIX at diagnosis (for histologically proven RCC). Comparing 91 RCC proven patients to 32 controls, they showed a significantly increased level of CAIX in RCC patients compared to controls [34]. Moreover, metastatic patients had higher rates of serum-circulating CAIX compared to those who had localized diseases. The median follow-up was 38 months for patients with a localized, surgically-managed disease. The comparison in plasmatic levels of CAIX showed higher rates in patients who experienced recurrence during follow-up, suggesting that an increased level of plasmatic CAIX at diagnosis is predictive of recurrence.
From another perspective, Liu et al. [35] developed an alternative technique to detect circulating tumor cells using ligands of membranous CAIX designed for RCC patients. They showed a significant positive association between circulating CAIX-RCC cells and disease progression, histological features and clinical staging. These results demonstrate the correlation between the serum levels of CAIX, RCC circulating cells and the tumor burden, aggressiveness and propensity of recurrence.

3.2.3. CAIX and Imaging

Current developments in molecular imaging taking advantage of biomarker tracking can overcome the limitations of conventional imaging (CT and MRI) for renal masses exploration. Those are often serendipitous and rarely permit a reliable prediction of tumor subtype or malignancy. Tumor biopsies have their technical limits: they are not contributive in more than 20% of cases [36]. By focusing on a very limited area they do not reflect the tumor heterogeneity [37]. The contribution of 18F-FDG PET/CT has been well-described [38]. Although it might detect RCC metastasis, it does not work for primary renal tumors and is not recommended in RCC exploration [39]. A recent molecular imaging tool targeting CAIX is girentuximab [40], also called cG250, an anti-CAIX chimeric antibody which allows PET/CT imaging when bonded with certain isotopes (131I, 124I or 111In) that furthermore leads a pathway to radioimmunotherapy (RIT) in ccRCC.
Another diagnostic approach employs ultrasound molecular imaging (USMI), using CAIX-targeted bubbles, allowing the detection of masses that express the marker. Facility, accessibility and innocuity are solid arguments for this technique [41]. Table 2 summarizes the evidence on the clinical value of CAIX targeting in molecular imaging.

CAIX and Conventional CT Scans

Young et al. published a study aiming to assess the correlation between the gross appearance of tumoral blood vessels on injected CT scans with the CAIX expression intensity in IHC [42]. The CAIX score (a technique developed by Chamie et al., described above) was determined by immunostaining on 105 ccRCC tumors.
High expression (range 200–300) of CAIX was more likely to show gross appearance of vessels on CT scan. The 4 phases CT-scan could potentially predict CAIX expression, correlated to the neovascularization propensity. Nonetheless, the other CT features did not correlate with the CAIX score (i.e., pattern of enhancement, necrosis, renal vein invasion).

Positron Emission Tomography

Lindenberg et al. [43] evaluated the potential of girentuximab, labeled with 124I when used as a PET/CT agent. They tested the radiotracer in a study with 195 patients scheduled for renal mass resection. The analyses showed 86% sensitivity and 86% specificity for detection of malignant tumor of the kidney (respectively 76% and 47% for contrast enhanced CT).
Hekman et al. [44] reported a clinical study using girentuximab labeled with 89Zr in PET/CT imaging. They showed a good capacity of 89Zr-girentuximab to predict ccRCC histology subtype in recently diagnosed renal masses, with all resected ccRCC being pre-operatively positive on molecular imaging. It also presented a good performance to rule out recurrence for previously treated patients, with no lesion progression or metastasis detected with enhanced CT-scan when 89Zr-gurentuximab PET-CT was negative.
Minn et al. [45] developed a novel dual motif ligand for PET/CT detection of localized and metastatic ccRCC. 64Cu-XYIMSR-06 is a small size synthesized molecule added with radioactive copper, presenting high affinity for CAIX. Experiments in vitro and in nude mice bearing human ccRCC xenografts showed interesting results, notably the advantageous pharmacokinetics facilitating the PET/CT imaging schedules compared to girentuximab: PET/CT acquisition 1 h to 1 day after injection vs. 2 to 6 days, respectively. No human utilization has been described yet.
Turkbey et al. [46] reported the results of a phase 2 clinical trial on a small molecule radiotracer targeting CAIX: 18F-VM4-037. Due to physiologic renal excretion, the tracer showed a low capacity to detect primary renal lesions (mean SUV 2.55; range 0.58–4.23, SD: 1.23). On the other hand, the detection of ccRCC metastasis was remarkable (mean SUV 5.92), comparable to 18F-FDG PET/CT imaging for detection of extra renal lesions.

Ultrasound Molecular Imaging (USMI)

Zhu et al. described a new USMI contrast product: CAIX aptamer-functionalized targeted nanobubbles [41]. As seen above, CAIX may be expressed by many different malignancies and it is a trans-membranous protein. The nanobubbles present a size specificity permitting the passive absorption by the tissues realizing an intratumoral cell targeting, where conventional microbubbles stay blocked in the vessels. They created the CAIX aptamer using a repeated PCR technique (a selection of one single-stranded DNA by screening the systematic evolution of ligands by exponential enrichment, 10 rounds). They tested the CAIX nanobubble USMI on xenografted nude mice with different malignant cell-lines. Human renal cell carcinoma 786-O cells and HeLa human cervical cancer cells, which are known to be CAIX-positive, and BPxPC-3 human pancreatic cancer cells, which are not for control. They also described the distribution, loading and binding ability of these nanobubbles, demonstrated by immunofluorescence. They controlled their experimentation with nanobubbles attached to a nonsense aptamer. The experimentation showed the ability of the nanobubbles to reach the tumor parenchyma, in addition to the tumor vascularization enhancing. The tumor CAIX immunostaining matched with the targeted nano-bubbles localization.

Fluorescence for Facilitation of Peroperative Recognition

CAIX-targeted agents are developed in order to facilitate the per operative recognition of small renal masses. This could allow for safer surgery and better resection margins when partial nephrectomy is indicated, with an objective to diminish the recurrence rate.
Muselaers et al. [47] first realized a preclinical study to validate the concept of guided surgery with G250, a dual labeling agent with 111In and a near infrared fluorophore (IRDye800CW). BALB/c nu/nu mice with intraperitoneal human derived ccRCC cellular lines received one injection of the CAIX targeting agent or a dual labeled irrelevant control antibody (four mice per group), and subsequently underwent a PET/CT scan once a week during five weeks. Fluorescence imaging were determined with ex vivo biodistribution studies. Results showed good concordance between PET/CT imaging, with maximum uptake of the radiotracer in the first week and fluorescence, with excellent delineation of the tumors.
Hekman et al. [48] subsequently tested the technique in a first-in-human phase 1 study, published in 2018. Dose escalation (5, 10, 30, or 50 mg) of CAIX-targeting antibody 111In-DOTA-girentuximab-IRDye800CW was performed in a cohort of 15 patients scheduled for small renal mass surgery. PET/CT was performed four days after injection and surgical intervention at day 7 with a gamma probe and a near-infrared fluorescence camera. Histological outcomes showed 12 ccRCC, all hyperfluorescent at any dose, all PET/CT positives and all presenting a stronger signal with per operative gamma camera. No study-related serious adverse events were noticed.

3.3. CAIX in Therapeutics

Several RCC therapeutic strategies focus on CAIX. It is a highly-expressed, specific surface antigen of ccRCC, allowing targeted treatments: vaccines and immunity sensitization or radioimmunotherapy using cG250/girentuximab. Blocking the CAIX expression in ccRCC might sensitize the tumor to external radiotherapy, reducing its pH regulation skills.

3.3.1. Vaccines and Immune-Mediating

The cell-mediated activation of anti-tumoral immunity remains in three steps: antigen presentation, activation of co-stimulatory signals and amplification of the immune response. Current research on these therapeutics remain mainly preclinical, awaiting in-human studies.
In 2008 Shuch et al. [49] reported a new vaccine strategies. The main one was the use of dendritic cells (DCs, specific tumor antigen presentation) via an introduction of a granulocyte-macrophage colony stimulating factor (GMCSF)-CAIX fusion protein (produced by viral bioengineering), in order to activate DCs and thus trigger a CD8+ mediated, CAIX targeted, antitumoral response. Kim et al. [50] presented the results of a pre-clinical study in 2011 aiming to activate DCs by a combination of CAIX and Acinetobacter baumannii outer membrane protein A (AbOmpA) in a murine model [51]. A significant immunostimulatory of DCs was observed via secretion of IL-2 and interferon (IFN)γ in T-cells. In 2013, Birkhäuser et al. [52] tested a dendritic cell vaccine in immunocompetent mice, showing encouraging results with significative tumoral growth inhibition, specifically in CAIX positives tumors.
In 2018, a phase 1, open-label, dose-escalation and cohort expansion study evaluated the safety and immune response to autologous dendritic cells transduced with AdGMCA9 (recombinant adenovirus encoding the GMCSF-CAIX fusion gene) in patients with metastatic renal cell carcinoma [53]. 15 patients were enrolled, among which nine received the planned treatment. They did not present any serious adverse event. This phase 1 protocol did not permit any efficiency statement.
Chang et al. [54] showed in a preclinical study the ability of human anti-CAIX antibodies to mediate immune cell inhibition of renal cell carcinoma. They demonstrated that human anti-CAIX mAbs fixation on CAIX expressive RCC led to an immune-mediated destruction of tumoral cells in vitro by antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and antibody-dependent cellular phagocytosis (ADCP). They also showed a migration inhibition of RCC cells in vitro. Administration of the same anti-CAIX human mAbs in an orthotopic RCC model utilizing allogeneic human peripheral blood mononuclear cells in NOD/SCID/ IL2Rγ−/− mice showed inhibition of tumor growth.

3.3.2. cG250/Girentuximab and Radioimmunotherapy

Oosterwijk et al. [55] published in 2011 the results of a preclinical study on nude mice bearing human RCC xenograft. The objective was to observe the effect of several tyrosine kinase inhibitors (TKIs): Sunitib, sorafenib or vandetanib on the bio-distribution of injected marked 125I-gerentuximab. Tumor growth and vascularization were significatively affected, probably due to the TKI therapy, however 125I-girentuximab accumulation in the tumor were drastically diminished in vivo and at gamma-detection. Nonetheless, the 125I-gerentuximab tumor-accumulation recovered after several days of TKI discontinuation. We should consider major interactions between cG250 and TKIs that must impose precaution in further trials testing cG250 on humans being treated. In 2013, the same team reviewed the state of the art concerning radioimmunotherapy using cG250/girentuximab labeled with radioisotopes in RCC as promising treatment [56]. Clinical studies realized between 1998 and 2011 were screened: seven phase I, three phase II (in metastatic RCC) and 1 phase III (in adjuvant setting for patients at high risk after nephrectomy, the ARISER study); showing limited benefice and suggesting a better efficiency for small-volume patients.
After Stillbroer et al. [57] determined the maximum tolerated dose of 177Lu-girentuximab in a phase I study, Muselaers et al. [58] evaluated in 2015, in a phase II non-randomized single-arm trial, the efficacy of 177Lu-girentuximab. Fourteen metastatic ccRCC patients with evidence of progressive disease were enrolled between April 2011 and August 2014. They received an 177Lu-girentuximab infusion (2405 MBq/m2), then clinical and radiological outcomes, according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1), were prospectively assessed. At first evaluation after the first infusion, eight patients (57%) had stable disease (SD) and 1 (7%) had partial response (PR). Hematological issues (prolonged low blood cell count) were the major adverse event (grade 3 or 4 myelotoxicity observed in almost all patients): five patients on six receiving the second infusion (75% of initial dose) had SD but prolonged thrombocytopenia, imposing treatment discontinuation.
The combined myelosuppressive activity of both TKIs and girentuximab might be a major obstacle for further development of this strategy [59].

3.3.3. Sensitization to Radiotherapy Inhibiting CAIX Expression

Duivenvoorden et al. [60] published a preclinical study suggesting the potential protective role of CAIX for irradiated tumors, as CAIX is a pH regulator. Introduction of a pharmacological CAIX inhibitor, or transfection with shRNA-mediated knockdown of CAIX, in xenografted nude mice with ccRCC (786-O cells) resulted in a better response (in vitro) to irradiation (6Gy), compared with mice receiving either irradiation or pharmacological alone. The tumors were significantly smaller in transfected mice (in vivo).

4. Conclusions

In conclusion, the place of CAIX remain prevalent from diagnosis to treatment and treatment response monitoring, especially for the clear cell subtype, the most common form of RCC. While the value of CAIX in immunohistochemistry is well established, the development of molecular imaging or treatment applications have not yet passed phase III clinical trial validations and remain more or less exploratory. However, rationale and first studies outcomes are encouraging and open the way for new advances in the management of the disease.

Author Contributions

Conceptualization, A.I. and N.L.; methodology, A.I. and J.C.; validation, A.I.; M.N. and I.L.; resources, A.I. and J.C.; writing—original draft preparation, A.I. and J.C.; writing—review and editing, A.d.l.T.; M.N.; I.L. and N.L.; supervision, A.I. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

Abbreviations

AbOmpAAcinetobacter baumannii outer membrane protein A
ADCCAntibody-dependent cell-mediated cytotoxicity
AdGMCA9adenovirus encoding the GMCSF-CAIX fusion gene
ADCPAntibody-dependent cellular phagocytosis
AMACRα-Methylacyl-CoA racemase
CAIXCarbonic anhydrase IX
ccpRCCMultilocular cystic renal neoplasm of low malignant potential
ccRCCClear cell renal cell carcinoma
CDCComplement-dependent cytotoxicity
chRCCChromophobe renal cell carcinoma
CKCytokeratine
CTComputed tomography
DCDendritic cell
FDGFluorodesoxyglucose
GMCFGranulocyte-macrophage colony stimulating factor
HIFHypoxia inducible factor
HREHypoxia responsive elements
IHCImmunohistochemistry
MRIMagnetic resonance imaging
PETPositron emission tomography
pRCCPapillary renal cell carcinoma
RCCRenal cell carcinoma
pVHLVon Hippel Lindau protein
RECISTResponse evaluation criteria in solid tumors
SDStandard deviation
SUVStandardized Uptake Value
TKITyrosine kinase inhibitor
TFE3Transcription factor binding to IGHM enhancer 3
USMIUltrasound molecular imaging
VEGFRVascular endothelial growth factor
WHOWorld Health Organization

References

  1. Ferlay, J.; Steliarova-Foucher, E.; Lortet-Tieulent, J.; Rosso, S.; Coebergh, J.W.W.; Comber, H.; Forman, D.; Bray, F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur. J. Cancer Oxf. Engl. 1990, 49, 1374–1403. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Professionals, S.-O. EAU Guidelines: Renal Cell Carcinoma, Uroweb. Available online: https://uroweb.org/guideline/renal-cell-carcinoma/ (accessed on 3 August 2020).
  3. Moch, H.; Cubilla, A.L.; Humphrey, P.A.; Reuter, V.E.; Ulbright, T.M. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur. Urol. 2016, 70, 93–105. [Google Scholar] [CrossRef] [PubMed]
  4. Benej, M.; Pastorekova, S.; Pastorek, J. Carbonic anhydrase IX: Regulation and role in cancer. In Carbonic Anhydrase: Mechanism, Regulation, Links to Disease, and Industrial Applications; Frost, S.C., McKenna, R., Eds.; Springer: Dordrecht, The Netherlands, 2014; Volume 75, pp. 199–219. [Google Scholar]
  5. Tafreshi, N.K.; Lloyd, M.C.; Bui, M.M.; Gillies, R.J.; Morse, D.L. Carbonic Anhydrase IX as an Imaging and therapeutic target for tumors and metastases. In Carbonic Anhydrase: Mechanism, Regulation, Links to Disease, and Industrial Applications; Frost, S.C., McKenna, R., Eds.; Springer: Dordrecht, The Netherlands, 2014; Volume 75, pp. 221–254. [Google Scholar]
  6. Opavský, R.; Pastoreková, S.; Zelník, V.; Gibadulinová, A.; Stanbridge, E.J.; Závada, J.; Kettmann, R.; Pastorek, J. HumanMN/CA9Gene, a Novel Member of the Carbonic Anhydrase Family: Structure and Exon to Protein Domain Relationships. Genomics 1996, 33, 480–487. [Google Scholar] [CrossRef]
  7. Swietach, P.; Wigfield, S.; Cobden, P.; Supuran, C.T.; Harris, A.L.; Vaughan-Jones, R.D. Tumor-associated Carbonic Anhydrase 9 Spatially Coordinates Intracellular pH in Three-dimensional Multicellular Growths. J. Biol. Chem. 2008, 283, 20473–20483. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  8. Wykoff, C.C.; Beasley, N.J.; Watson, P.H.; Turner, K.J.; Pastorek, J.; Sibtain, A.; Wilson, G.D.; Turley, H.; Talks, K.L.; Maxwell, P.H.; et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000, 60, 7075–7083. [Google Scholar]
  9. Maxwell, P.H.; Wiesener, M.; Chang, G.W.; Clifford, S.C.; Vaux, E.C.; Cockman, M.E.; Wykoff, C.C.; Pugh, C.W.; Maher, E.R.; Ratcliffe, P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399, 271–275. [Google Scholar] [CrossRef]
  10. Pastoreková, S.; Parkkila, S.; Parkkila, A.K.; Opavský, R.; Zelník, V.; Saarnio, J.; Pastorek, J. Carbonic anhydrase IX, MN/CA IX: Analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology 1997, 112, 398–408. [Google Scholar] [CrossRef]
  11. Svastová, E.; Zilka, N.; Zat’ovicová, M.; Gibadulinová, A.; Ciampor, F.; Pastorek, J.; Pastoreková, S. Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with beta-catenin. Exp. Cell Res. 2003, 290, 332–345. [Google Scholar] [CrossRef]
  12. Renal Cell Carcinoma Overview. Available online: http://www.pathologyoutlines.com/topic/kidneytumormalignantrcc.html (accessed on 22 July 2020).
  13. Kim, M.; Joo, J.W.; Lee, S.J.; Cho, Y.A.; Park, C.K.; Cho, N.H. Comprehensive Immunoprofiles of Renal Cell Carcinoma Subtypes. Cancers 2020, 12, 602. [Google Scholar] [CrossRef] [Green Version]
  14. Reuter, V.E.; Argani, P.; Zhou, M.; Delahunt, B.; Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group. Best practices recommendations in the application of immunohistochemistry in the kidney tumors: Report from the International Society of Urologic Pathology consensus conference. Am. J. Surg. Pathol. 2014, 38, e35–e49. [Google Scholar] [CrossRef]
  15. Alshenawy, H.A. Immunohistochemical Panel for Differentiating Renal Cell Carcinoma with Clear and Papillary Features. Pathol. Oncol. Res. POR 2015, 21, 893–899. [Google Scholar] [CrossRef] [PubMed]
  16. Ljungberg, B.; Bensalah, K.; Canfield, S.; Dabestani, S.; Hofmann, F.; Hora, M.; Kuczyk, M.A.; Lam, T.; Marconi, L.; Merseburger, A.S.; et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur. Urol. 2015, 67, 913–924. [Google Scholar] [CrossRef] [PubMed]
  17. Bing, Z.; Lal, P.; Lu, S.; Ziober, A.; Tomaszewski, J.E. Role of carbonic anhydrase IX, α-methylacyl coenzyme a racemase, cytokeratin 7, and galectin-3 in the evaluation of renal neoplasms: A tissue microarray immunohistochemical study. Ann. Diagn. Pathol. 2013, 17, 58–62. [Google Scholar] [CrossRef] [PubMed]
  18. Truong, L.D.; Shen, S.S. Immunohistochemical diagnosis of renal neoplasms. Arch. Pathol. Lab. Med. 2011, 135, 92–109. [Google Scholar] [CrossRef]
  19. Ingels, A.; Hew, M.; Algaba, F.; de Boer, O.J.; van Moorselaar, R.J.A.; Horenblas, S.; Zondervan, P.; de la Rosette, J.J.M.C.H.; Pilar Laguna Pes, M. Vimentin over-expression and carbonic anhydrase IX under-expression are independent predictors of recurrence, specific and overall survival in non-metastatic clear-cell renal carcinoma: A validation study. World J. Urol. 2016. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  20. Bui, M.H.T.; Seligson, D.; Han, K.; Pantuck, A.J.; Dorey, F.J.; Huang, Y.; Horvath, S.; Leibovich, B.C.; Chopra, S.; Liao, S.-Y.; et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2003, 9, 802–811. [Google Scholar]
  21. Zhang, B.Y.; Thompson, R.H.; Lohse, C.M.; Dronca, R.S.; Cheville, J.C.; Kwon, E.D.; Leibovich, B.C. Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up: CAIX is not an independent predictor of outcome in patients with ccRCC. BJU Int. 2013, 111, 1046–1053. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Zerati, M.; Leite, K.R.M.; Pontes-Junior, J.; Segre, C.C.; Reis, S.T.; Srougi, M.; Dall’Oglio, M.F. Carbonic Anhydrase IX is not a predictor of outcomes in non-metastatic clear cell renal cell carcinoma—A digital analysis of tissue microarray. Int. Braz J. Urol Off. J. Braz. Soc. Urol. 2013, 39, 484–492. [Google Scholar] [CrossRef] [Green Version]
  23. Büscheck, F.; Fraune, C.; Simon, R.; Kluth, M.; Hube-Magg, C.; Möller-Koop, C.; Shadanpour, N.; Bannenberg, C.; Eichelberg, C.; Höflmayer, D.; et al. Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma. Urol. Oncol. Semin. Orig. Investig. 2018, 36, 531.e19–531.e25. [Google Scholar] [CrossRef]
  24. Samberkar, S.; Rajandram, R.; Mun, K.S.; Samberkar, P.; Danaee, M.; Zulkafli, I.S. Carbonic anhydrase IX immunohistochemistry has potential to predict renal cell carcinoma outcomes: A systematic review and meta-analyses. Malays. J. Pathol. 2019, 41, 233–242. [Google Scholar]
  25. Patard, J.-J.; Fergelo, T.P.; Karakiewicz, P.I.; Klatte, T.; Trinh, Q.-D.; Rioux-Leclercq, N.; Said, J.W.; Belldegrun, A.S.; Pantuck, A.J. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma: CAIX and VHL Status in Kidney Cancer. Int. J. Cancer 2008, 123, 395–400. [Google Scholar] [CrossRef] [Green Version]
  26. Chamie, K.; Klöpfer, P.; Bevan, P.; Störkel, S.; Said, J.; Fall, B.; Belldegrun, A.S.; Pantuck, A.J. Carbonic anhydrase-IX score is a novel biomarker that predicts recurrence and survival for high-risk, nonmetastatic renal cell carcinoma: Data from the phase III ARISER clinical trial. Urol. Oncol. Semin. Orig. Investig. 2015, 33, 204.e25–204.e33. [Google Scholar] [CrossRef]
  27. Tostain, J.; Li, G.; Gentil-Perret, A.; Gigante, M. Carbonic anhydrase 9 in clear cell renal cell carcinoma: A marker for diagnosis, prognosis and treatment. Eur. J. Cancer Oxf. Engl. 1990, 46, 3141–3148. [Google Scholar] [CrossRef] [PubMed]
  28. Atkins, M.; Regan, M.; McDermott, D.; Mier, J.; Stanbridge, E.; Youmans, A.; Febbo, P.; Upton, M.; Lechpammer, M.; Signoretti, S. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2005, 11, 3714–3721. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  29. Escudier, B.; Porta, C.; Schmidinger, M.; Rioux-Leclercq, N.; Bex, A.; Khoo, V.; Grünwald, V.; Gillessen, S.; Horwich, A. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2019, 30, 706–720. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  30. Choueiri, T.K.; Regan, M.M.; Rosenberg, J.E.; Oh, W.K.; Clement, J.; Amato, A.M.; McDermott, D.; Cho, D.C.; Atkins, M.B.; Signoretti, S. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int. 2010, 106, 772–778. [Google Scholar] [CrossRef]
  31. Choueiri, T.K.; Cheng, S.; Qu, A.Q.; Pastorek, J.; Atkins, M.B.; Signoretti, S. Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET). Urol. Oncol. 2013, 31, 1788–1793. [Google Scholar] [CrossRef] [Green Version]
  32. Lucarini, L.; Magnelli, L.; Schiavone, N.; Crisci, A.; Innocenti, A.; Puccetti, L.; Cianchi, F.; Peri, S.; Supuran, C.T.; Papucci, L.; et al. Plasmatic carbonic anhydrase IX as a diagnostic marker for clear cell renal cell carcinoma. J. Enzyme Inhib. Med. Chem. 2018, 33, 234–240. [Google Scholar] [CrossRef] [Green Version]
  33. Pirinççi, N.; Kaya, T.Y.; Kaba, M.; Ozan, T.; Geçit, İ.; Özveren, H.; Eren, H.; Ceylan, K. Serum adenosine deaminase, catalase, and carbonic anhydrase activities in patients with renal cell carcinoma. Redox Rep. Commun. Free Radic. Res. 2017, 22, 252–256. [Google Scholar] [CrossRef] [Green Version]
  34. Li, G.; Feng, G.; Gentil-Perret, A.; Genin, C.; Tostain, J. Serum carbonic anhydrase 9 level is associated with postoperative recurrence of conventional renal cell cancer. J. Urol. 2008, 180, 510–513, discussion 513–514. [Google Scholar] [CrossRef]
  35. Liu, S.; Tian, Z.; Zhang, L.; Hou, S.; Hu, S.; Wu, J.; Jing, Y.; Sun, H.; Yu, F.; Zhao, L.; et al. Combined cell surface carbonic anhydrase 9 and CD147 antigens enable high-efficiency capture of circulating tumor cells in clear cell renal cell carcinoma patients. Oncotarget 2016, 7, 59877–59891. [Google Scholar] [CrossRef] [PubMed]
  36. Ingels, A.; Barret, E.; Sanchez-Salas, R.; Galiano, M.; Rozet, F.; Lenoir, S.; Weber, N.; Audenet, F.; Cathelineau, X. Percutaneous Renal Biopsies for Small Renal Masses: Complex Tumors on Nephrometry Should Be the First Targets. Clin. Genitourin. Cancer 2016, 14, e457–e462. [Google Scholar] [CrossRef] [PubMed]
  37. Gerlinger, M.; Rowan, A.J.; Horswell, S.; Larkin, J.; Endesfelder, D.; Gronroos, E.; Martinez, P.; Matthews, N.; Stewart, A.; Tarpey, P.; et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012, 366, 883–892. [Google Scholar] [CrossRef] [Green Version]
  38. Wang, H.-Y.; Ding, H.-J.; Chen, J.-H.; Chao, C.-H.; Lu, Y.-Y.; Lin, W.-Y.; Kao, C.-H. Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma. Cancer Imaging 2012, 12, 464–474. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  39. Ljungberg, B.; Albiges, L.; Abu-Ghanem, Y.; Bensalah, K.; Dabestani, S.; Fernández-Pello, S.; Giles, R.H.; Hofmann, F.; Hora, M.; Kuczyk, M.A.; et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. Eur. Urol. 2019, 75, 799–810. [Google Scholar] [CrossRef] [PubMed]
  40. Muselaers, S.; Mulders, P.; Oosterwijk, E.; Oyen, W.; Boerman, O. Molecular imaging and carbonic anhydrase IX-targeted radioimmunotherapy in clear cell renal cell carcinoma. Immunotherapy 2013, 5, 489–495. [Google Scholar] [CrossRef]
  41. Zhu, L.; Wang, L.; Liu, Y.; Xu, D.; Fang, K.; Guo, Y. CAIX aptamer-functionalized targeted nanobubbles for ultrasound molecular imaging of various tumors. Int. J. Nanomedicine 2018, 13, 6481–6495. [Google Scholar] [CrossRef] [Green Version]
  42. Young, J.R.; Coy, H.; Kim, H.J.; Douek, M.; Sisk, A.; Pantuck, A.J.; Raman, S.S. Association of the Gross Appearance of Intratumoral Vascularity at MDCT with the Carbonic Anhydrase IX Score in Clear Cell Renal Cell Carcinoma. Am. J. Roentgenol. 2018, 211, 1254–1258. [Google Scholar] [CrossRef]
  43. Lindenberg, L.; Mena, E.; Choyke, P.L.; Bouchelouche, K. PET imaging in renal cancer. Curr. Opin. Oncol. 2019, 31, 216–221. [Google Scholar] [CrossRef]
  44. Hekman, M.C.H.; Rijpkema, M.; Aarntzen, E.H.; Mulder, S.F.; Langenhuijsen, J.F.; Oosterwijk, E.; Boerman, O.C.; Oyen, W.J.G.; Mulders, P.F.A. Positron Emission Tomography/Computed Tomography with 89Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion. Eur. Urol. 2018, 74, 257–260. [Google Scholar] [CrossRef]
  45. Minn, I.; Koo, S.M.; Lee, H.S.; Brummet, M.; Rowe, S.P.; Gorin, M.A.; Sysa-Shah, P.; Lewis, W.D.; Ahn, H.-H.; Wang, Y.; et al. [64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma. Oncotarget 2016, 7, 56471–56479. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Turkbey, B.; Lindenberg, M.L.; Adler, S.; Kurdziel, K.A.; McKinney, Y.L.; Weaver, J.; Vocke, C.D.; Anver, M.; Bratslavsky, G.; Eclarinal, P.; et al. PET/CT imaging of renal cell carcinoma with (18)F-VM4-037: A phase II pilot study. Abdom. Radiol. N. Y. 2016, 41, 109–118. [Google Scholar] [CrossRef] [PubMed]
  47. Muselaers, C.H.J.; Rijpkema, M.; Bos, D.L.; Langenhuijsen, J.F.; Oyen, W.J.G.; Mulders, P.F.A.; Oosterwijk, E.; Boerman, O.C. Radionuclide and Fluorescence Imaging of Clear Cell Renal Cell Carcinoma Using Dual Labeled Anti-Carbonic Anhydrase IX Antibody G250. J. Urol. 2015, 194, 532–538. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  48. Hekman, M.C.; Rijpkema, M.; Muselaers, C.H.; Oosterwijk, E.; Hulsbergen-Van de Kaa, C.A.; Boerman, O.C.; Oyen, W.J.; Langenhuijsen, J.F.; Mulders, P.F. Tumor-targeted Dual-modality Imaging to Improve Intraoperative Visualization of Clear Cell Renal Cell Carcinoma: A First in Man Study. Theranostics 2018, 8, 2161–2170. [Google Scholar] [CrossRef] [PubMed]
  49. Shuch, B.; Li, Z.; Belldegrun, A.S. Carbonic anhydrase IX and renal cell carcinoma: Prognosis, response to systemic therapy, and future vaccine strategies. BJU Int. 2008, 101, 25–30. [Google Scholar] [CrossRef] [PubMed]
  50. Kim, B.R.; Yang, E.K.; Kim, S.H.; Moon, D.C.; Kim, H.J.; Lee, J.C.; Kim, D.Y. Immunostimulatory activity of dendritic cells pulsed with carbonic anhydrase IX and Acinetobacter baumannii outer membrane protein A for renal cell carcinoma. J. Microbiol. Seoul Korea 2011, 49, 115–120. [Google Scholar] [CrossRef] [Green Version]
  51. Kim, B.-R.; Yang, E.-K.; Kim, D.-Y.; Kim, S.-H.; Moon, D.-C.; Lee, J.-H.; Kim, H.-J.; Lee, J.-C. Generation of anti-tumour immune response using dendritic cells pulsed with carbonic anhydrase IX-Acinetobacter baumannii outer membrane protein A fusion proteins against renal cell carcinoma. Clin. Exp. Immunol. 2012, 167, 73–83. [Google Scholar] [CrossRef] [Green Version]
  52. Birkhäuser, F.D.; Koya, R.C.; Neufeld, C.; Rampersaud, E.N.; Lu, X.; Micewicz, E.D.; Chodon, T.; Atefi, M.; Kroeger, N.; Chandramouli, G.V.R.; et al. Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: Efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models. J. Immunother. Hagerstown Md 1997, 36, 102–111. [Google Scholar] [CrossRef]
  53. Faiena, I.; Zomorodian, N.; Comin-Anduix, B.; Sachadeva, A.; Bot, A.; Kabinnivar, F.; Said, J.W.; Cheung-Lau, G.; Pang, J.; Macabali, M.; et al. A phase I, open-label, dose-escalation and cohort expansion study evaluating the safety and immune response to autologous dendritic cells transduced with AdGMCA9 in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2018, 36, 653. [Google Scholar] [CrossRef]
  54. Chang, D.-K.; Moniz, R.J.; Xu, Z.; Sun, J.; Signoretti, S.; Zhu, Q.; Marasco, W.A. Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo. Mol. Cancer 2015, 14, 119. [Google Scholar] [CrossRef] [Green Version]
  55. Oosterwijk-Wakka, J.C.; Kats-Ugurlu, G.; Leenders, W.P.J.; Kiemeney, L.A.L.M.; Old, L.J.; Mulders, P.F.A.; Oosterwijk, E. Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250. BJU Int. 2011, 107, 118–125. [Google Scholar] [CrossRef] [PubMed]
  56. Oosterwijk-Wakka, J.C.; Boerman, O.C.; Mulders, P.F.A.; Oosterwijk, E. Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma. Int. J. Mol. Sci. 2013, 14, 11402–11423. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  57. Stillebroer, A.B.; Boerman, O.C.; Desar, I.M.E.; Boers-Sonderen, M.J.; van Herpen, C.M.L.; Langenhuijsen, J.F.; Smith-Jones, P.M.; Oosterwijk, E.; Oyen, W.J.G.; Mulders, P.F.A. Phase 1 Radioimmunotherapy Study with Lutetium 177–labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma. Eur. Urol. 2013, 64, 478–485. [Google Scholar] [CrossRef] [PubMed]
  58. Muselaers, C.H.J.; Boers-Sonderen, M.J.; van Oostenbrugge, T.J.; Boerman, O.C.; Desar, I.M.E.; Stillebroer, A.B.; Mulder, S.F.; van Herpen, C.M.L.; Langenhuijsen, J.F.; Oosterwijk, E.; et al. Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma. Eur. Urol. 2016, 69, 767–770. [Google Scholar] [CrossRef]
  59. Pal, S.K.; Agarwal, N. Kidney cancer: Finding a niche for girentuximab in metastatic renal cell carcinoma. Nat. Rev. Urol. 2016, 13, 442–443. [Google Scholar] [CrossRef]
  60. Duivenvoorden, W.C.M.; Hopmans, S.N.; Gallino, D.; Farrell, T.; Gerdes, C.; Glennie, D.; Lukka, H.; Pinthus, J.H. Inhibition of carbonic anhydrase IX (CA9) sensitizes renal cell carcinoma to ionizing radiation. Oncol. Rep. 2015, 34, 1968–1976. [Google Scholar] [CrossRef] [Green Version]
Ijms 21 07146 g001 550
Figure 1. Clear cell renal cell carcinoma. Hematoxylin and eosin staining. The tumor shows solid alveolar growth pattern with regular network of small thin-walled blood vessels. Neoplastic cells have clear cytoplasm filled with lipids and surrounded by distinct cell membranes.
Figure 1. Clear cell renal cell carcinoma. Hematoxylin and eosin staining. The tumor shows solid alveolar growth pattern with regular network of small thin-walled blood vessels. Neoplastic cells have clear cytoplasm filled with lipids and surrounded by distinct cell membranes.
Ijms 21 07146 g001
Ijms 21 07146 g002 550
Figure 2. CAIX staining of a clear cell renal cell carcinoma. Tumor cells exhibit diffuse CAIX membranous immunoreactivity.
Figure 2. CAIX staining of a clear cell renal cell carcinoma. Tumor cells exhibit diffuse CAIX membranous immunoreactivity.
Ijms 21 07146 g002
Ijms 21 07146 g003 550
Figure 3. Clear cell papillary renal cell carcinoma. Cells display CA IX positivity with cup-like distribution.
Figure 3. Clear cell papillary renal cell carcinoma. Cells display CA IX positivity with cup-like distribution.
Ijms 21 07146 g003
Table
Table 1. Evidence synthesis of CAIX application for immunohistochemistry and its predictive value for clinical outcomes.
Table 1. Evidence synthesis of CAIX application for immunohistochemistry and its predictive value for clinical outcomes.
Common CAIX Expression in Immunohistochemistry
RCC subtypeCAIXCK7
ccRCC+++−
pRCCI−+
pRCCII+/−+/−
chRCC−+
ccpRCC++
multilocular cystic renal neoplasms+/−+
Predictive value of CAIX expression
StudyRCC subtypeResults
Ingels et al. [19]ccRCCCAIX expression < 30% in IHC associated with diminished OS, PFS and DFS
Bui et al. [20]ccRCCLow CAIX expression associated with unfavorable disease course
Buschek et al. [23]ccRCCHigh CAIX expression was associated with better outcomes
Buschek et al. [23]pRCCAbnormal expression of CAIX was associated with diminished PFS
Samberkar et al. [24]ccRCCHigh CAIX expression associated with lower tumor grade and stage, N0, favorable ECOG score
Chamie et al. [26]ccRCCHigh CAIX score > 200 associated with prolonged DFS and OS
ccRCC: clear cell renal cell carcinoma. pRCCI: papillary renal cell carcinoma. pRCCII: papillary renal cell carcinoma. chRCC: chromophobe renal cell caricnoma. ccpRCC: clear cell papillary renal cell carcinoma. OS: overall survival. PFS: progression free survival. DFS: disease free survival. ECOG: Eastern cooperative oncology group. CAIX: carbonic ahydrase IX. CK7: cytokeratin 7. +++: expression is almost systematic +: classically positive −: classically negative +/−: variable.
Table
Table 2. Evidence synthesis of CAIX application for molecular imaging.
Table 2. Evidence synthesis of CAIX application for molecular imaging.
USMI
Studyproduct abilitieslimitations
Zhu et al. [41]CAIX aptamer functionalized nanobubblesEnhance vascularization and parenchyma in CAIX-expressive tumorsPreclinical data only
PET imaging
Studyproductabilitieslimitations
Lindenberg et al. [43]
Hekman et al. [44]		Girentuximab/cG250Good sensitivity and specificity for ccRCC
many labeling possibilities with several isotopes (124I, 131I, 111In, 89Zr etc.)		Slow pharmacokinetics, acquisition within 2 to 6 days
Lindenberg et al. [43]18FDGDetection of metastasisLow sensitivity for primary tumor
Minn et al. [45]64Cu-XYIMSR-06Fast pharmacokinetics, acquisition within 1 h to 1 dayPreclinical data only
Turkbey et al. [46]18F-VM4-037Sensitivity for metastasis detection could be better than 18FDGLow sensitivity for primary tumor
USMI: ultrasound molecular imaging. PET: positron emission tomography. Girentuximab: chimeric IgG1 monoclonal antibody to carbonic anhydrase IX. 18FDG: 18-flurodesoxyglucose. 18F-VM4-037 is a small molecule radiotracer targeting carbonic anhydrase IX. 64Cu-XYIMSR-06 is a small molecule radiotracer targeting carbonic anhydrase IX.

Share and Cite

MDPI and ACS Style

Courcier, J.; de la Taille, A.; Nourieh, M.; Leguerney, I.; Lassau, N.; Ingels, A. Carbonic Anhydrase IX in Renal Cell Carcinoma, Implications for Disease Management. Int. J. Mol. Sci. 2020, 21, 7146. https://doi.org/10.3390/ijms21197146

AMA Style

Courcier J, de la Taille A, Nourieh M, Leguerney I, Lassau N, Ingels A. Carbonic Anhydrase IX in Renal Cell Carcinoma, Implications for Disease Management. International Journal of Molecular Sciences. 2020; 21(19):7146. https://doi.org/10.3390/ijms21197146

Chicago/Turabian Style

Courcier, Jean, Alexandre de la Taille, Maya Nourieh, Ingrid Leguerney, Nathalie Lassau, and Alexandre Ingels. 2020. "Carbonic Anhydrase IX in Renal Cell Carcinoma, Implications for Disease Management" International Journal of Molecular Sciences 21, no. 19: 7146. https://doi.org/10.3390/ijms21197146

APA Style

Courcier, J., de la Taille, A., Nourieh, M., Leguerney, I., Lassau, N., & Ingels, A. (2020). Carbonic Anhydrase IX in Renal Cell Carcinoma, Implications for Disease Management. International Journal of Molecular Sciences, 21(19), 7146. https://doi.org/10.3390/ijms21197146

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop